212 related articles for article (PubMed ID: 28659916)
1. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
Erbe AK; Wang W; Reville PK; Carmichael L; Kim K; Mendonca EA; Song Y; Hank JA; London WB; Naranjo A; Hong F; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Miller JS; Gilman AL; Kahl B; Yu AL; Sondel PM
Front Immunol; 2017; 8():675. PubMed ID: 28659916
[TBL] [Abstract][Full Text] [Related]
2. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Erbe AK; Wang W; Carmichael L; Hoefges A; Grzywacz B; Reville PK; Ranheim EA; Hank JA; Kim K; Seo S; Mendonca EA; Song Y; Kenkre VP; Hong F; Gascoyne RD; Paietta E; Horning SJ; Miller JS; Kahl B; Sondel PM
J Immunother Cancer; 2019 Mar; 7(1):70. PubMed ID: 30871628
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Erbe AK; Wang W; Carmichael L; Kim K; Mendonça EA; Song Y; Hess D; Reville PK; London WB; Naranjo A; Hank JA; Diccianni MB; Reisfeld RA; Gillies SD; Matthay KK; Cohn SL; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Gilman AL; Yu AL; Sondel PM
Clin Cancer Res; 2018 Jan; 24(1):189-196. PubMed ID: 28972044
[No Abstract] [Full Text] [Related]
4. HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
Thöns C; Senff T; Hydes TJ; Manser AR; Heinemann FM; Heinold A; Heilmann M; Kim AY; Uhrberg M; Scherbaum N; Lauer GM; Khakoo SI; Timm J
J Hepatol; 2017 Sep; 67(3):462-470. PubMed ID: 28412292
[TBL] [Abstract][Full Text] [Related]
5. The impact of killer cell immunoglobulin-like receptor (KIR) genes and human leukocyte antigen (HLA) class I ligands on predisposition or protection against prostate cancer.
Roshan Zamir M; Ariafar A; Ghaderi A; Amirzargar A
Immunobiology; 2023 Mar; 228(2):152319. PubMed ID: 36599262
[TBL] [Abstract][Full Text] [Related]
6. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
Forlenza CJ; Boudreau JE; Zheng J; Le Luduec JB; Chamberlain E; Heller G; Cheung NK; Hsu KC
J Clin Oncol; 2016 Jul; 34(21):2443-51. PubMed ID: 27069083
[TBL] [Abstract][Full Text] [Related]
7. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
[TBL] [Abstract][Full Text] [Related]
8. KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing.
Carlomagno S; Falco M; Bono M; Alicata C; Garbarino L; Mazzocco M; Moretta L; Moretta A; Sivori S
Front Immunol; 2017; 8():581. PubMed ID: 28603523
[TBL] [Abstract][Full Text] [Related]
9. KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis.
Umemura T; Joshita S; Saito H; Yoshizawa K; Norman GL; Tanaka E; Ota M
JHEP Rep; 2019 Nov; 1(5):353-360. PubMed ID: 32039386
[TBL] [Abstract][Full Text] [Related]
10. HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia.
Komic H; Hallner A; Hussein BA; Badami C; Wöhr A; Hellstrand K; Bernson E; Thorén FB
Cancer Immunol Immunother; 2023 Nov; 72(11):3559-3566. PubMed ID: 37597015
[TBL] [Abstract][Full Text] [Related]
11. KIR3DL1 and HLA-Bw4 Interaction Showed a Favorable Role in Patients with Myelodysplastic Syndromes in Chinese Southern Han.
Zhen JX; Cai SQ; Chen YT; Yang ZC; Zhuo JC; Deng ZH
Biomed Res Int; 2020; 2020():6215435. PubMed ID: 32420357
[TBL] [Abstract][Full Text] [Related]
12. HLA-Bw4 in association with KIR3DL1 favors natural killer cell-mediated protection against severe COVID-19.
Wang R; Sun Y; Kuang BH; Yan X; Lei J; Lin YX; Tian J; Li Y; Xie X; Chen T; Zhang H; Zeng YX; Zhao J; Feng L
Emerg Microbes Infect; 2023 Dec; 12(1):2185467. PubMed ID: 36849422
[TBL] [Abstract][Full Text] [Related]
13. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
14. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
Erbe AK; Diccianni MB; Mody R; Naranjo A; Zhang FF; Birstler J; Kim K; Feils AS; Hung JT; London WB; Shulkin BL; Mathew V; Parisi MT; Servaes S; Asgharzadeh S; Maris JM; Park J; Yu AL; Sondel PM; Bagatell R
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822669
[TBL] [Abstract][Full Text] [Related]
15. Decreased interferon-γ production by NK cells from KIR haplotype B carriers in hepatitis C virus infection.
Mele D; Pasi A; Cacciatore R; Mantovani S; Oliviero B; Mondelli MU; Varchetta S
Liver Int; 2019 Jul; 39(7):1237-1245. PubMed ID: 31177636
[TBL] [Abstract][Full Text] [Related]
16. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.
Feils AS; Erbe AK; Birstler J; Kim K; Hoch U; Currie SL; Nguyen T; Yu D; Siefker-Radtke AO; Tannir N; Tolaney SM; Diab A; Sondel PM
Cancer Immunol Immunother; 2023 Jul; 72(7):2099-2111. PubMed ID: 36823323
[TBL] [Abstract][Full Text] [Related]
17. Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival.
Beksac K; Beksac M; Dalva K; Karaagaoglu E; Tirnaksiz MB
PLoS One; 2015; 10(7):e0132526. PubMed ID: 26181663
[TBL] [Abstract][Full Text] [Related]
18. KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and Old World monkeys.
Schafer JL; Colantonio AD; Neidermyer WJ; Dudley DM; Connole M; O'Connor DH; Evans DT
J Immunol; 2014 Feb; 192(4):1907-17. PubMed ID: 24453246
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory natural killer cell receptor KIR3DL1 with its ligand Bw4 constraints HIV-1 disease among South Indians.
Maruthamuthu S; Rajalingam R; Pandian K; Madasamy S; Manoharan M; Pitchai L; Murugesan A; Mariakuttikan J
AIDS; 2018 Nov; 32(18):2679-2688. PubMed ID: 30289808
[TBL] [Abstract][Full Text] [Related]
20. HLA alleles determine differences in human natural killer cell responsiveness and potency.
Kim S; Sunwoo JB; Yang L; Choi T; Song YJ; French AR; Vlahiotis A; Piccirillo JF; Cella M; Colonna M; Mohanakumar T; Hsu KC; Dupont B; Yokoyama WM
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3053-8. PubMed ID: 18287063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
